James Herndon

Emory University
United States

Cheng Hu

Technetium Therapeutics
United States

Xulin Li

, China

PAPER Rehman H, Ang TF, Tao Q, Au R, Farrer LA, Qiu WQ, Zhang X, Alzheimer's Disease Neuroimaging Initiative

Plasma protein risk scores for mild cognitive impairment and Alzheimer's disease in the Framingham heart study.

Alzheimers Dement. 2025 Mar;21(3):e70066. PubMed.

PAPER Li X, Liu C, Li W, Qi G, Dai Y, Gu C, Sun Y, Zhou W, Ciliberto VC, Liang J, Kumar S U, Guan D, Hu Z, Zheng H, Liu Z, Chen H, Wan YW, Sun Z

Multi-omics delineate growth factor network underlying exercise effects in an Alzheimer's mouse model.

Alzheimers Dement. 2025 Mar;21(3):e70024. PubMed.

PAPER Shaker MR, Salloum-Asfar S, Taha RZ, Javed I, Wolvetang EJ

Klotho overexpression protects human cortical neurons from β-amyloid induced neuronal toxicity.

Mol Brain. 2025 Mar 28;18(1):27. PubMed.

PAPER Zargaham MK, Ibrahim A, Ahmed M, Babar MM, Rajadas J

Targeting amyloidogenic proteins through cyclic peptides- A medicinal chemistry perspective.

Bioorg Med Chem. 2025 Mar 19;123:118165. Epub 2025 Mar 19 PubMed.

PAPER Fukui R, Hafizal U, Kageyama Y, Irie Y, Matsushima Y, Hosoi K, Nakayama T, Kaneda D, Hashizume Y, Miki K, Kita A, Mukaisho KI, Kushima R, Tooyama I, Irie K

Identification of the binding site and immunoreactivity of anti-Aβ antibody 11A1: Comparison with the toxic conformation-specific TxCo-1 antibody.

Biochem Biophys Res Commun. 2025 Apr 12;758:151655. Epub 2025 Mar 17 PubMed.

PAPER Rabinovici GD, Selkoe DJ, Schindler SE, Aisen P, Apostolova LG, Atri A, Greenberg SM, Hendrix SB, Petersen RC, Weiner M, Salloway S, Cummings J

Donanemab: Appropriate use recommendations.

J Prev Alzheimers Dis. 2025 Mar 27;:100150. Epub 2025 Mar 27 PubMed.

PAPER Donaghy PC, Hasoon J, Hamilton CA, Ciafone J, Durcan R, Barnett N, Olsen K, Lawley S, Greenfinch G, Firbank M, Heslegrave A, Zetterberg H, Allan L, O'Brien JT, Taylor JP, Thomas AJ

Plasma Biomarkers and Disease Prognosis in Mild Cognitive Impairment with Lewy Bodies.

Mov Disord. 2025 Mar 29; Epub 2025 Mar 29 PubMed.

PAPER Ossenkoppele R, Salvadó G, Janelidze S, Pichet Binette A, Bali D, Karlsson L, Palmqvist S, Mattsson-Carlgren N, Stomrud E, Therriault J, Rahmouni N, Rosa-Neto P, Coomans EM, van de Giessen E, van der Flier WM, Teunissen CE, Jonaitis EM, Johnson SC, Villeneuve S, PREVENT-AD Research Group, Benzinger TL, Schindler SE, Bateman RJ, Doecke JD, Doré V, Feizpour A, Masters CL, Rowe C, Wiste HJ, Petersen RC, Jack CR Jr, Hansson O

Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials.

Nat Aging. 2025 Mar 28; Epub 2025 Mar 28 PubMed.

PAPER Jahng GH, Lee MB, Kwon OI

Gadolinium based contrast agent induced electrical conductivity heterogeneity analysis in the brain of Alzheimer's disease.

Sci Rep. 2025 Mar 28;15(1):10832. PubMed.

PAPER Kim HK, Park S, Kim SW, Park ES, Hong JY, Hong I, Baek MS

Association between L-α glycerylphosphorylcholine use and delayed dementia conversion: A nationwide longitudinal study in South Korea.

J Prev Alzheimers Dis. 2025 Apr;12(4):100059. Epub 2025 Jan 10 PubMed.

PAPER Wang J, Huang S, Lan G, Lai YJ, Wang QH, Chen Y, Xiao ZS, Chen X, Bu XL, Liu YH, Zeng F, Zhang L, Li A, Cai Y, Sun P, He Z, Doré V, Fripp J, Bourgeat P, Chen Q, Yu JT, Tang Y, Zetterberg H, Masters CL, Guo T, Wang YJ, Translational Biomarker Research of AgIng and Neurodegeneration (TBRAIN)

Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts.

Alzheimers Dement. 2025 Mar;21(3):e70038. PubMed.

PAPER Rogers B

Unraveling temporal patterns of diagnostic markers and comorbidities in Alzheimer's disease: Insights from large-scale data.

Alzheimers Dement. 2025 Mar;21(3):e14564. PubMed.